Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Acting on peptide bonds (3.4) (e.g., urokinease, etc.)

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424940100 - ENZYME OR COENZYME CONTAINING

424940600 - Hydrolases (3. ) (e.g., urease, lipase, asparaginase, muramidase, etc.)

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424940640 Serine proteinases (3.4.21) (e.g., trypsin, chymotrypsin, plasmin, thrombin, elastase, kallikrein, fibrinolysin, streptokinease, etc.) 230
424940670 Metalloproteinases (3.4.24) (e.g., collagenase, snake venom zinc proteinase, etc.) 55
424940650 SH-proteinases (3.4.22) (e.g., papain, chymopapain, bromelains, ficin, etc.) 35
424940660 Acid proteinases (3.4.23) (e.g., pepsin, renin, chymosin, etc.) 1
20090136478Methods for using enzymes to disintegrate cancerous tumors in vivo - Methods to disintegrate cancerous tissue in vivo, using proteolytic enzyme compound for the digestion of the cancer cells. These methods exploit the fact that there is a significant difference in the strength and layout of the protein fraction between the normal and the cancer cells.05-28-2009
Entries
DocumentTitleDate
20120244140SCREENING METHOD FOR SUBSTANCE CAPABLE OF PROMOTING RECOVERY OF SKIN BARRIER FUNCTION TECHNICAL FIELD - The present invention provides a screening method for a substance capable of promoting recovery of skin barrier function, wherein the method comprises the steps of incubating caspase-14 and prosaposin in the presence of a candidate substance for the substance capable of promoting recovery of skin barrier function, and selecting the candidate substance as the substance capable of promoting recovery of skin barrier function when the degradation of prosaposin into saposin A is promoted significantly compared to a control substance.09-27-2012
20090130084Tagged IgA1 proteases - The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.05-21-2009
20120183525FIBRINOGENOLYTIC ENZYME TABFIBLYSIN OF HORSEFLY, TABANUS YAO, ENCODING GENE AND USE THEREOF - A horsefly protease tabfiblysin isolated from the salivary gland of the horsefly, Tabanus Yao, a gene encoding the protease and use thereof are disclosed by the present invention. It belongs to the technical field of biomedicine. The molecular weight of the horsefly protease tabfiblysin is 27145.5 Daltons. Its full-length sequence is composed of 255 amino acids. Its encoding sequence is composed of 768 nucleotides. The horsefly protease tabfiblysin can hydrolyze fibrinogen and inhibit the aggregation of blood platelet dramatically, and can be used for preparing the drug for treating thrombotic diseases.07-19-2012
20100129342Human Growth and Differentiation Factor GDF-5 - This invention relates to the production and use of pharmaceutical growth factor compositions with novel characteristics, e.g. improved solubility and controlled release characteristics under physiological conditions. Said compositions of one or more precursor proteins of growth factors of the GDF family provoke morphogenic effects such as for example growth, differentiation, protection and regeneration of a variety of tissues and organs, e.g. bone, cartilage, tendons, ligaments, nerves and skin. The invention can be advantageously used for the healing of tissue-destructive injuries and for the prevention or therapy of degenerative disorders.05-27-2010
20080317732Amyloid Peptide Inactivating Enzyme to Treat Alzheimer's Disease Peripherally - Methods for treatment and/or prevention of Alzheimer's disease comprising inactivating peripheral AP in serum to a reduce A(3 in the brain. Methods comprise expression of amyloid peptide inactivating enzyme on bone marrow cells; and coupling of amyloid peptide inactivating enzyme to hematopoietic cells.12-25-2008
20090280106Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use - This invention provides peptides with novel modifications that provide suitable derivatization sites to improve the pharmacokinetic properties of the peptides. These modified peptides function in vivo as agonists of the VPAC2 receptor. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, for example, type 2 diabetics.11-12-2009
20090155239Novel Protease, Microorganism Producing the Same, and Application Thereof - An object of the present invention are to provide a protease that is stable in a wide pH range from acidic to alkaline, and that has excellent thrombolytic activity; a protease-producing microorganism that produces the above protease; and a process for producing the protease.06-18-2009
20100040596USE OF MATRIX METALLOPROTEINASE-10 (MMP-10) FOR THROMBOLYTIC TREATMENTS - The present invention relates to the use of matrix metalloproteinase MMP-10 in the preparation of a pharmaceutical composition useful for thrombolytic therapy, it also being possible for said composition to contain a plasminogen activator. Additionally, the present invention relates to said pharmaceutical composition for the treatment of thrombotic disorders.02-18-2010
20130045195Proteases for Degrading Gluten - Gluten-degrading proteases derived from insects, including flour beetles, are isolated, and the purified, and recombinant forms can be used to make gluten-containing food safe for patients suffering from gluten intolerance.02-21-2013
20130034535METHOD FOR TREATING OBESITY WITH ANTI-OBESITY FORMULATIONS AND OMEGA 3 FATTY ACIDS FOR THE REDUCTION OF BODY WEIGHT IN CARDIOVASCULAR DISEASE PATIENTS (CVD) AND DIABETICS - Combinations of one or more anti-obesity drugs with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight comprised of a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA comprise about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics.02-07-2013
20130089536PHARMACEUTICAL COMPOSITION TO PREVENT AND TREAT ALZHEIMER'S DISEASE COMPRISING GCP II MUTANT - The present invention relates to a GCP II (glutamate carboxypeptidase II) mutant (K699S) having the activity of inhibiting glutamate production and the activity of cleavaging β-amyloid, and to a pharmaceutical composition for the prevention and treatment of a disease selected from the group consisting of amyloidosis, Alzheimer's disease, Down syndrome accompanying Alzheimer's disease, stroke, dementia, Huntington's disease, Pick's disease, and Creutzfeldt-Jakob disease comprising the GCP II mutant (K699S) as an active ingredient. The GCP II (glutamate carboxypeptidase II) mutant (K699S) demonstrates not only excellent Aβ cleavage activity compared with the wild type GCP II but also excellent activity of inhibiting glutamate production, unlike the wild type GCP II, so that the mutant has been confirmed to have higher effect and stability than the wild type, suggesting that the GCP II mutant can be effectively used for the prevention or treatment of neurodegenerative diseases.04-11-2013
20090041746Combination therapy with IgA1 proteases - The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.02-12-2009
20090041745MODULATORS OF PARAPTOSIS AND RELATED METHODS - The invention is directed to a method of modulating paraptotic cell death in a cell by contacting the cell with an effective amount of a compound selected from the group consisting of ceramide, Tumor Necrosis Factor (TNF), caspase-7, caspase-8, α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA), kainic acid and glutamic acid, wherein the effective amount of the compound induces paraptotic death of the cell. The invention further is directed to a method of inhibiting paraptotic cell death in a cell by contacting the cell with an effective amount of a compound selected from the group consisting of Alg-2-interacting protein 1 (AIP-1), Jun N-terminal kinase 1 (JNK1) neutralizing agent, Jun N-terminal kinase 2 (JNK2) neutralizing agent, TNF Receptor-Associated Factor 2 (TRAF2) neutralizing agent, ortho-phenanthroline and the JNK inhibitor SP 600125, wherein the effective amount of the compound inhibits paraptotic death of the cell.02-12-2009
20090269327Protein having prolyl oligopeptidase activity, nucleic acid encoding same and method for producing and using same - Proteins isolated from 10-29-2009
20120225049FAST ACTING SNARE-CLEAVING ENZYMES - The present invention relates to metalloprotease enzymes isolated from scorpion venom, their nucleic acid and amino acid sequences, and methods of use thereof in the treatment of various diseases, disorders and cosmetic conditions.09-06-2012
20090232789NOVEL PHARMACEUTICAL PREPARATION FOR PREECLAMPSIA, ECLAMPSIA, AND TOXEMIA, AND THEIR RELATED SYMPTOMS AND RELATED DISORDERS OF PREGNANCY - A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the maternal GI tract to determine the likelihood of developing preeclampsia, pregnancy induced hypertension, and eclampsia/toxemia is disclosed.09-17-2009
20120114628COSMETIC AND THERAPEUTIC USE OF PROTEINS OF DJ-1 TYPE FOR TREATING SKIN DRYNESS - The present invention relates to the use, especially the cosmetic and/or therapeutic use, of the protein DJ-1, of polypeptides derived from this protein or of analogues thereof, of a nucleic acid sequence coding for such a polypeptide or of a modulator of the activity, stability or expression of such a polypeptide, especially for preventing and/or treating the signs of skin dryness. The invention also relates to the use of the protein DJ-1, of polypeptides derived from this protein or of analogues thereof or of a nucleic acid sequence coding for such a polypeptide, as a marker for evaluating the state of dryness of an epithelium.05-10-2012
20090010916C-1 Inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis - A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous conversion to tcuPA in blood at therapeutic concentrations. Two-chain M5 was shown to form complexes with C1-inhibitor, which was the principal inhibitor of tcM5 in plasma. The effect of supplemental additions of C1-inhibitor on fibrinolysis and fibrinogenolysis by M5 was determined. Supplemental C1-inhibitor restored the stability of high-dose M5 and prevented fibrinogenolysis but not fibrinolysis, the rate of which was not compromised by the inhibitor. Due to higher dose tolerance of M5 in the presence of supplemental C1-inhibitor, the rate of fibrin-specific lysis reached that achievable by nonspecific fibrinolysis, which is the maximum possible for a plasminogen activator. Plasma C1-inhibitor stabilized M5 in plasma by inhibiting tcM5 which would otherwise greatly amplify non-specific plasminogen activation causing more tcM5 generation from M5. This unusual dissociation of inhibitory effects, whereby fibrinogenolysis and not fibrinolysis is inhibited, has significant implications for improving the safety and efficacy of fibrinolysis. Methods of reducing bleeding and non-specific plasminogen activation during fibrinolysis by administering M5 along with exogenous C1-inhibitor are disclosed.01-08-2009
20080305099Pharmaceutical Composition, Composition for Screening Therapeutics Preventing and Treating Beta Amyloid Accumulation in Brain Comprising Gcp II (Glutamate Carboxypeptidase II) as an Active Ingredient and Method for Screening Using the Same - The present invention relates to a pharmaceutical composition for the prevention and treatment for β-amyloid(Aβ) accumulation in brain comprising GCP-II (Glutamate carboxypeptidase-II) as an active ingredient, a composition for screening method of the same. GCP-II of the present invention not only degrades Aβ monomer and oligomer but also degrades soluble Aβ and insoluble Aβ, particularly aggregated Aβ, so that it can prevent the accumulation of Aβ in brain or reduce the accumulation, making it an excellent candidate for the therapeutic agent for Alzheimer's disease and Down's syndrome.12-11-2008
20090130083Therapeutic Agents Targeting the NCCA-ATP Channel and Methods of Use Thereof - The present invention is directed to therapeutic compositions targeting the NC05-21-2009
20080267944Process for Obtaining Recombinant Prothrombin Activating Protease (Rlopap) in Monomeric form; the Recombinant Prothrombin Activating Protease (Rlopap) as Well as its Amino Acid Sequence; the Use of this Protease as a Defibrinogenase - This invention refers to the process for obtaining the recombinant prothrombin activating protease (rLopap) in monomeric form, the recombinant prothrombin activating protease (rLopap), as well as its amino acid sequence. In addition to that, this invention also refers to the use of this protease for depleting the blood fibrinogen, and serve as diagnosis kit for dysprothrombinemias. This invention describes the obtainence in recombinant form and the characterization of a prothrombin activator protease of 21 kDa, named rLopap (10-30-2008
20110286995Drug Therapy for Celiac Sprue - Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.11-24-2011
20110286994METHODS AND COMPOSITIONS FOR IMPROVING GROWTH OF MEAT-TYPE POULTRY - The present invention provides methods of improving growth performance, improving the efficiency of feed utilization, increasing feed digestibility, and decreasing mortality of immature and developing animals receiving animal feed. Methods of producing a crude keratinase enzyme extract and animal feed supplements for achieving the same are also provided.11-24-2011
20090311238TOPICAL COMPOSITION AND TREATMENT METHOD FOR CARTILAGE DAMAGE - A method of treating cartilage damage by topically administering an effective amount of a pharmaceutical composition comprising (a) a substance P inhibitor and (b)a proteolytic enzyme with an suitable pharmaceutical carrier. The pharmaceutical composition is capable of promoting cartilage regeneration in animal and human subjects.12-17-2009
20100098682Effect of Bri Proteins on Ass Production - Provided are methods for reducing inhibiting or preventing Aβ and/or AID production by a cell and methods of treating a subject having Alzheimer's disease. Also provided are methods of determining whether a compound is a mimic of a BRI2 or a BRI3. Additionally provided are pharmaceutical compositions of BRI2, BRI3 or furin, or vectors encoding those proteins.04-22-2010
20090263373NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE - The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire 10-22-2009
20090142329Interleukin-1 Beta Converting Enzyme Like Apoptosis Protease-3 and 4 - Disclosed are human interleukin-1 β converting enzyme like apoptosis proteases-3 and 4 and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Also provided are methods of using the polypeptides, for example, as an antitumor agent, and antiviral agent, and antibodies and antagonists against such polypeptides for example, for treating Alzheimer's disease, Parkinson's disease, rheumatoid arthritis and head injury. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases are also disclosed.06-04-2009
20080206224MUSCLE CONTRACTION TREATMENT UTILIZING BOTULINUM TOXIN - The invention provides for the use of a 08-28-2008
20090104176COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS - One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.04-23-2009
20090285793Novel thrombolytic enzyme and a process for its preparation - The invention relates to a thrombolytic enzyme referred to as Thrombinase having a molecular weight of 31,000 to 32,000. Such a thrombolytic enzyme can be used for dissolving blood clots. The process comprises culturing a filtrate of Bacillus sphaericus sero type H5a 5b, removing the cell, subjecting the cell supernatant to filtration, salting out the retentate, subjecting the precipitate to dialysis, reprecipitating the precipitate and then reconstituting in buffer and finally decolourizing, purifying and dialyzing.11-19-2009
20100278806Composition Containing Arazyme for the Prevention and Treatment of Arthritis - Disclosed herein is a composition containing arazyme as an active ingredient for prevention and treatment of arthritis. More specifically, arazyme produced from 11-04-2010
20090169538Methods of Treating or Preventing Tissue Damage Caused by Increased Blood Flow - A method of treating or preventing tissue damage occurring subsequent to affecting an increase in blood flow through a blood vessel which is in communication with the tissue, by administering an effective amount of a composition including a tissue damage-reducing or -preventing polypeptide including at least one of Thymosin beta 4 (TB4), an isoform of TB4, an N-terminal fragment of TB4, a C-terminal fragment of TB4, TB4 sulfoxide, an LKKTET [SEQ ID NO: 1] peptide, an LKKTNT [SEQ ID NO: 2] peptide, an actin-sequestering peptide, an actin binding peptide, an actin-mobilizing peptide, an actin polymerization-modulating peptide, or a conservative variant thereof having tissue damage-reducing activity. The composition is administered to the tissue before, during and/or after affecting the increase in blood flow.07-02-2009
20100129343Use Of A Compound For Enhancing The Expression Of Membrane Proteins On The Cell Surface - The present invention is directed to the use of a compound stimulating deubiquitinating activity in a cell for the manufacture of a medicament for enhancing the expression of integral membrane proteins on the cell surface. Especially, the invention is directed to the use of such compound for the manufacture of a medicament for the treatment of a disease of condition selected from the group consisting of cystic fibrosis, diabetes insipidus, hypercholesterinaemia and long QT-syndrome-2.05-27-2010
20080292611NOVEL METHODS OF TREATMENT AND DELIVERY MODES - The invention relates to a novel method of administration, and device employed in the method, for administering a treatment species to the lungs of a recipient patient. The method involves introducing the device of the invention to the venous system of the patient, the size of the treatment species being such that, upon introduction to the venous system of the patient, the device will impact in a region of a lung capillary of the patient. The treatment species gains access to the lung and/or lung epithelia due to proteases associated with the treatments species. The application of the method to the treatment of cystic fibrosis is also claimed.11-27-2008
20080311103Anti-Inflammatory Peptides and Methods of Use Thereof - Anti-inflammatory peptides derived from naturally occurring digests of proteins including apolipoprotein A-I, apolipoprotein A-II, fibrinogen γ chain, fibrinogen Aa, low-density lipoprotein receptor, ADAM 8, cadherin 4, and calcitonin receptor are provided, along with pharmaceutical compositions comprising same and methods of treating inflammatory diseases using same.12-18-2008
20080233102Drug Therapy for Celiac Sprue - Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.09-25-2008
20080241122Dental Composition Comprising Enzyme - The present invention relates to a dental composition comprising an enzyme having an enzyme activity at acidic pH values, a buffer providing an acidic pH value and one or more preservative agents, wherein at least one preservative agent is active at acidic pH.10-02-2008
20080233103Mycobacterial peptide deformylase - The present invention relates to the design of the Antisense-oligonucleotide complementary to the specific region of peptide deformylase gene from 09-25-2008
20080317735Pharmaceutical preparation with RNA as hemostasis cofactor - Pharmaceutical preparations which comprise RNA or one or more coagulation-promoting fragments of RNA in amounts sufficient to promote coagulation and to promote fibrinolysis are described. They are in particular advantageously employed together with an activator for hemostatic processes such as factor VII-activating protease (FSAP)12-25-2008
20080317734NUTRACEUTICAL COMPOSITIONS AND METHODS WITH BIOLOGICALLY ACTIVE INGREDIENTS - Nutraceutical formulations are personalized to address an individual's nutrient deficiencies. Growth factors and high doses of inefficiently absorbed nutrients are nanoencapsulated and delivered orally to improve the function, health, and appearance of the individual.12-25-2008
20090162341Non-Cytotoxic Protein Conjugates - A non-cytotoxic protein conjugate for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell, comprising: (i) a Targeting Moiety (TM), wherein said TM is an agonist of a receptor present on said nociceptive sensory afferent cell, and wherein said receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of said nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described.06-25-2009
20090142328Uses of antileukoprotease in carcinoma - The present invention provides a method of detecting/monitoring tumor growth and progression in a tissue by measuring the level of antileukoprotease. Also provided is a method of treating an individual having a tumor by administering antileukoprotease to inhibit the activity of stratum corneum chymotryptic enzyme. Specifically, the tumor is an ovarian carcinoma.06-04-2009
20100178286METHODS AND COMPOSITIONS FOR REDUCING FACIAL LINES AND WRINKLES - A dietary supplement composition comprising a therapeutically effective amount of at least one sirt 1 activating agent, a therapeutically effective amount of at least one Qi activating agent, and an therapeutically effective amount of at least one adaptogen is disclosed. An optional herbal treatment for stress-related deep wrinkles comprises chronic oral administration for at least two weeks of a beverage containing an effective amount of a valerian root extract sufficient to provide a desired reduction in the appearance of the deep wrinkles. A photoprotective agent may also be included. Also included are a microcirculation increasing agent. Also optional are an herbal toner and topical cellulite product.07-15-2010
20100226909Method And Apparatus For Producing Autologous Thrombin - A device for isolating a component of a multi-component composition. The device includes a housing, a chamber, and a withdrawal port. The chamber is rotatably mounted within the housing. The chamber includes a chamber base and a sidewall. The side wall extends from the chamber base. At least a portion of the sidewall is defined by a filter that permits passage of a first component of the multi-component composition out of the chamber through the filter and to the housing base. The filter restricts passage of a second component of the multi-component composition through the filter. The withdrawal port extends from a position proximate to the housing base to an exterior of the device. The withdrawal port permits the withdrawal of the first component from the housing base to an exterior of the device.09-09-2010
20090017006USE OF A COMPOUND FOR ENHANCING THE EXPRESSION OF MEMBRANE PROTEINS ON THE CELL SURFACE - The present invention is directed to the use of Bortezomib and/or a pharmaceutically acceptable salt or ester thereof for the manufacture of a medicament for enhancing the expression of membrane proteins on the cell surface. Especially, the invention is directed to the use of Bortezomib for the manufacture of a medicament for the treatment of a disease of condition selected from the group consisting of cystic fibrosis, diabetes insipidus, hypercholesterinaemia and long QT-syndrome-2.01-15-2009
20120244139Modified proteases that inhibit complement activation - Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorder.09-27-2012
20080274097BOOSTER FOR THERAPY OF DISEASES WITH ULTRASOUND AND PHARMACEUTICAL LIQUID COMPOSITION CONTAINING THE SAME - A booster comprising a plurality of microbubbles of a gas in a liquid, e.g. about 4×1011-06-2008
20110117074METHODS OF TREATING HIV AND INFLUENZA INFECTIONS USING ASPERGILLUS ORYZAE PROTEASE - The invention provides methods for treating viral diseases such as HIV infection and influenza infection in a subject in need of treatment, comprising orally administering to the subject a composition comprising a therapeutically effective amount of an 05-19-2011
20110086017Medical Food composition and methods for management of inflammatory processes in mammals - A medical food composition, containing at least source of milk protein derived from milk producing animals, exposed to immune stimulants during pregnancy and lactation period, source of Curcuminoids, source of proteolytic enzymes, and source of Piperin effective to manage inflammatory response and associated pain symptoms in mammals.04-14-2011
20100135984Anti-inflammatory compositions and methods - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that modulate at least one inflammatory response or reaction. According to various embodiments, the compositions, methods, devices, and systems relate to modulating one or more of Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.06-03-2010
20100135983Anti-inflammatory compositions and methods - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that modulate at least one inflammatory response or reaction. According to various embodiments, the compositions, methods, devices, and systems relate to modulating one or more of Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.06-03-2010
20110243916MODIFIED ENDOLYSIN PLY511 - The present invention relates to polypeptides with a changed amino acid sequence on at least one amino acid position compared to the amino acid sequence according to SEQ ID NO: 1. The present invention further relates to the nucleotide sequences encoding the polypeptide, vectors, comprising the nucleotide sequences and host cells for expression of the polypeptide. The present invention further relates to the use of the polypeptides as a human, veterinary medical or diagnostic substance, in food, in cosmetics, as disinfectant or in the environmental field.10-06-2011
20090004174Fusion Proteins - The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endocome within the target cell; a protease cleaving site at which site the fusion protein is cleavable by the protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and the translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell.01-01-2009
20100047227NOVEL ANTICANCER CATHEPSIN FORMULATIONS AND ANTICANCER AGENT FOR USE IN COMBINED ANTICANCER THERAPY - An anticancer cathepsin preparation contains, as the active ingredient, cathepsin E and/or an active fragment consisting of the active site thereof or containing the active site thereof. The anticancer cathepsin preparation inhibits the growth of cancer cells alone and prevents the metastasis thereof without exerting any undesirable effect on normal cells. Moreover, it can induce apoptosis in cancer cells. When used in combination with another anticancer agent, it can potentiate the sensitivity thereof, even to a cancer to which the existing anticancer agent shows no sensitivity. Owing to the sensitivity potentiating effect, the therapeutic effect on cancer can be remarkably enhanced. By potentiating the sensitivity of the anticancer agent, furthermore, the dose of the anticancer agent per se can be decreased and, in its turn, the side effects, etc. of the anticancer agent can be largely reduced.02-25-2010
20100034802TREATMENT OF PAIN - Use of a therapeutic molecule, for the treatment of specific pain conditions, wherein the therapeutic molecule is a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent.02-11-2010
20110086018PROTEINASES DESTROY CANCER TUMOR'S SOLID STRUCTURE AND KILL CANCER CELLS LOCALLY - A proteinase therapy has been invented to eliminate solid tumors by destroying tumors' solid structure and killing cancer cells by cleaving vital extracellular matrix proteins C-terminally, N-terminally or both with cell membrane intact and limited adverse effects. The micro-scale intratumoral proteinase K therapy is tumor specific but not cancer type specific. Proteinase K therapy can be operated on multiple tumors on multiple occasions, if necessary. It may be employed to eliminate any solid tumor to prolong a cancer patient's life span.04-14-2011
20110177056NON-CYTOTOXIC FUSION PROTEINS COMPRISING EGF MUTEINS - The present invention relates to fusion proteins comprising a non-cytotoxic protease and a EGF mutein ligand. The EGF mutein provides improved EGF receptor activation for the claimed fusion proteins. Also provided is the use of said polypeptides as therapeutics for suppressing mucus hypersecretion, inflammation, endocrine neoplasia and/or neuroendocrine disorders, neuroendocrine tumours, for suppressing cancers such as colorectal cancer, prostate cancer, breast cancer, and lung cancer.07-21-2011
20110076260Proteases Producing an Altered Immunogenic Response and Methods of Making and Using the Same - The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins.03-31-2011
20100310546ACE2 Polypeptide - The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life.12-09-2010
20090324576PHAGE DERIVED ANTIMICROBIAL ACTIVITIES - The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions.12-31-2009
20090317374COMPOSITION CONTAINING ARAZYME FOR THE PREVENTION AND TREATMENT OF CANCER - The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by 12-24-2009
20090317373Inhibition of the Anti-FVIII Immune Response - The invention relates to a compound capable of inhibiting the endocytosis of FVIII (factor VIII) by immune system cells capable of endocytosing the antigen and to the therapeutic use of such a compound for the manufacture of a medicament for use in the treatment of hemophiliacs in order to reduce the immunogenicity of FVIII and/or increase the half-life of FVIII.12-24-2009
20080219966METHODS OF TREATING PERVASIVE DEVELOPMENT DISORDERS - A therapeutic method for treating an individual diagnosed with PDD pervasive developmental disorder comprises determining the efficacy of digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level. A method for reducing the amount of methylphenidate (Ritalin) being taken by an individual with attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) by administering a therapeutic amount of digestive enzymes is also provided.09-11-2008
20090214512METHODS OF TREATING SKIN DISEASE, SCALP DISEASE, SENSITIVE SKIN OR SUPPRESSING HAIR LOSS WITH MICROBUBBLE WASHING COMPOSITIONS - The present invention provides a microbubble washing composition for washing a human body or an animal, a microbubble washing method using the microbubble washing composition, and a microbubble washing apparatus suitable for carrying out the method are provided which are capable of safely removing sebum and old keratin adhering to the surfaces of the pores in a short period of time, keeping the skin clean for a long period of time, preventing an odor. Specifically, the present invention provides a microbubble washing composition for washing a human body or an animal including a protease and a lipase, a microbubble washing method for washing a human body or an animal including washing a human body or an animal using a washing liquid containing the washing composition and microbubbles, and a microbubble washing apparatus.08-27-2009
20110135626Localized Chemical Lysis of Ocular Tissue - A high-intensity pulsed-electrical-field (HIPEF) apparatus chemically induces lysis of ocular tissue within a localized portion of an eye. Instead of broadly applying a lysis affecting solution (e.g., plasmin) to the eye, the apparatus delivers solution to only a portion of the eye. The apparatus then alters the effectiveness of at least some of the solution delivered by applying a HIPEF to that solution. In some embodiments, for example, the apparatus delivers a solution that does not substantially affect lysis of ocular tissue and then enhances the solution's effectiveness by applying a HIPEF. As the apparatus applies the HIPEF with high precision, the HIPEF only enhances the effectiveness of the solution within select and localized portions of the eye. The apparatus is especially advantageous for vitreoretinal surgery, whereby the apparatus may selectively induce lysis of vitreous tissue within a localized portion of the vitreous cavity, without significantly affecting adjacent retinal tissue.06-09-2011
20110020316COMPOSITION AND METHOD TO ALLEVIATE JOINT PAIN - Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found with krill oil and/or marine oil in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.01-27-2011
20110027256FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.02-03-2011
20100284996Assays for Detection of Von Willebrand Factor (vWF) Multimers and for Degradation of vWF by Agents Such as Adamts13 and Related Methods - Methods of analyzing the electrophoretic mobility distribution of von Willebrand factor (vWF) multimers include providing a sample medium comprising a plurality vWF multimers. The vWF multimers are electrophoretically separated by electrohoretic mobility in the sample medium by subjecting said sample medium to an electric field to provide separated vWF multimers. The separated vWF multimers in the sample medium are exposed to a light source to produce scattered light. The scattered light is detected, and the electrophoretic mobility distribution of the separated vWF multimers is determined from the detected scattered light.11-11-2010
20110135625CONTROLLED RELEASE ENZYMATIC COMPOSITION AND METHODS OF USE - The invention relates to an enzyme-containing gel composition capable of controlling enzymatic release and increasing the enzymatic activity level. When the composition includes at least one enzyme derived from Antarctic krill, it is efficient in cleansing wounds and accelerating healing, achieved in significant part by a glycol and/or glycerol gel capable of sustaining enzymatic release and/or enzymatic activity. The krill enzyme-containing gel may also be used to correct skin disorders, sterilize instruments, and facilitate transplants and treating fungal infections, bacterial infections, parasitic infections, hemorrhoids, corneal scarring, dental plaque, acne, cystic fibrosis, blood clots, immune disorders, autoimmune diseases and cancer.06-09-2011
20100055086Antimicrobial Flush Solutions - The present invention provides antimicrobial solutions that comprise at least one alcohol, at least one antimicrobial agent and at least one chelator and/or anticoagulant. Also provided are methods for rapidly reducing a microbe or a virus from surfaces including surfaces of indwelling medical devices and organic surfaces such as skin and sutures, and inorganic surfaces such as hospital equipment, pipelines etc.03-04-2010
20100322917PHARMACEUTICAL COMPOSITION CONTAINING ARAZYME FOR THE PREVENTION OF LIVER DYSFUNCTION - The present invention relates to a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme as an active ingredient, more precisely a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme produced by 12-23-2010
20100196347BONE GRAFTS WITH REDUCED PROTEASE ACTIVITY AND METHODS OF SELECTION AND USE - The invention features bone grafts (such as bone allografts) with reduced protease activity. These bone grafts are useful, for example, in conjunction with a polypeptide of interest (such as platelet derived growth factor) for treating, stabilizing, preventing, and/or delaying a bone, periodontium, ligament, cartilage, or tendon condition in an individual (such as a human). Additionally, the invention provides methods of measuring the protease activity associated with a bone graft, reducing the level of protease activity associated with a bone graft, selecting a bone graft with an acceptable level of protease activity, and methods of administering a bone graft and a polypeptide of interest to an individual.08-05-2010
20100196346NOVEL SUBSTRATE FOR RPN 11 ENZYMATIC ACTIVITY - The present application provides peptides that serve as substrates for proteasome enzymatic activity, e.g., the enzymatic activity of Rpn11, a metalloprotease of the 19S regulatory particle. The present application also provides methods and compositions employing the peptide substrates.08-05-2010
20110189158CLOSTRIDIAL NEUROTOXINS WITH ALTERED PERSISTENCY - The invention relates to a polypeptide comprising: 08-04-2011
20110189159METHODS AND COMPOSITIONS FOR PROTEIN DELIVERY - The present invention provides methods and compositions for protein delivery. The invention features virus like particles, methods of making virus like particles and methods of using virus like particles to deliver proteins to a cell, to provide protein therapy and to treat diseases or disorders. The invention also features methods of targeting a protein to a cell, methods of protein therapy and methods of treating diseases or disorders using a TUS protein, a NLS or NES identified from full length TUS.08-04-2011
20110262423SUPPRESSION OF CANCER - The present invention relates to polypeptides for use in suppressing cancer and cancer disorders. The treatment employs use of a non-cytotoxic protease, which is targeted to the cancer cell, and, when so delivered, the protease is internalised and inhibits secretion from the cancer cell.10-27-2011
20080292610Medicaments containing enzymes from ciliates for promoting digestion in digestive disorders - A medicament containing enzymes from ciliates selected from the group consisting of hydrolases, lipases, proteases, amylases, glycosidases, phospholipases, phosphodiesterases, phosphatases.11-27-2008
20090035294LIPOPOLYSACCHARIDE FRACTIONS OF VITREOSCILLA FILIFORMIS USEFUL FOR STIMULATING THE SYNTHESIS OF ANTI-MICROBIAL PEPTIDES OF THE SKIN - Specific fractions of 02-05-2009
20080292612COMPOSITION CONTAINING SEVERAL BOTULIC TOXINS - The invention concerns a composition including at least one botulinum neurotoxin type A1, and one botulinum neurotoxin type A the amino acid sequence of which as at least 5% difference with the amino acid sequence of botulinum neurotoxin type A1.11-27-2008
20110020315TREATMENT OF INFLAMMATORY ILLNESSES WITH ACE2 - The present invention relates to ACE2 for the therapeutic treatment or prevention of inflammation.01-27-2011
20090104174Methods and compositions for reducing the appearance of dynamic facial wrinkles - The present invention relates to methods and compositions for reducing the appearance of dynamic facial wrinkles by administering oral and/or topical compositions comprising therapeutically-effective amounts of extracts of one or more relaxing herbal agents (“RHAs”) alone or in combination with one or more extracts of an edible solanaceous glycoalkaloid-containing plant (“ESGP”) or an edible glycoalkaloid-containing fungus (“EGF”) selected from plant species in the genus 04-23-2009
20080274096Fusion Proteins Having a Modulated Half-Life in Plasma - The present invention relates to fusion proteins and their use in enzymatic treatment of Alzheimer's disease patients. Said fusion protein comprises a component that cleaves the amyloid beta (Ab) peptide e.g. neprilysin, insulin degrading enzyme (IDE), another component that modulates the half-life in plasma e.g. the Fc portion of IgG or PEG; and a third component that connects the first two components.11-06-2008
20090104175USE OF CASPASES FOR THE PREPARATION OF MEDICAMENTS - The invention relates to caspases and to extracellular use of caspases for regulating cell functions.04-23-2009
20100291063PROTEASE INHIBITION - The invention relates to a method for inhibiting an adam protease, comprising inhibiting binding to an integrin-binding loop of a disintegrin domain in the adam protease. Also provided are cyclic peptides which inhibit binding to an integrin-binding loop of an adam protease, as well as associated pharmaceutical compositions, uses and methods of treatment.11-18-2010
20100221236Mutants of Staphylokinase Carrying Amino and Carboxy-Terminal Extensions for Polyethylene Glycol Conjugation - The present invention relates to the development of new derivatives of a bacterial plasminogen activator, Staphylokinase (SAK), having one or more amino acid residues with single or multiple cysteines at the amino and/or carboxy terminal ends and their conjugation with PEG (Polyethylene Glycol), resulting in new Staphylokinase derivatives that display altered oligomeric states, enhanced thermal and protease stability and extended plasma half-life. Also included is the cloning and expression in a suitable bacterial host; purification of Staphylokinase derivatives to homogeneity and their chemical modification by integrating a PEG molecule to create new biologically active Staphylokinases having higher protein stability and improved in vivo plasma half life, that may enhance the clinical potential of Staphylokinase in thrombolytic therapy for the treatment of cardiovascular diseases.09-02-2010
20080317733Cosmeceutical Compositions and Methods with Biologically Active Ingredients - Cosmeceutical formulations are personalized to address an individual's nutrient deficiencies and genetic predispositions for premature aging of the skin. Growth factors and high doses of inefficiently absorbed nutrients are nanoencapsulated and delivered topically to improve the function, health, and appearance of skin and hair.12-25-2008
20090186012PLANT EXTRACT - The present invention relates generally to plant extracts and/or components isolated therefrom which exhibit desirable properties in relation to therapy. More particularly, the present invention relates to extracts and components isolated thereof from the plant genus 07-23-2009
20110318329METHOD OF TREATMENT OR PROPHYLAXIS - The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin II receptor 2 (AT12-29-2011
20090175842DIETARY ANTI-BACTERIAL COMPOSITIONS - A synergistic dietary antibacterial composition comprising the combination of proteolytic enzymes and one or more antibiotics effective against 07-09-2009
20120114629IGA1 PROTEASE POLYPEPTIDE AGENTS AND USES THEREOF - Polypeptide agents useful in the treatment of IgA1 deposition diseases and methods of using such polypeptide agents. Methods of screening for inhibitors of IgA1 proteases and agents that inhibit IgA1 proteases are also disclosed.05-10-2012
20120003204COMPOSITION CONTAINING ARAZYME FOR THE PREVENTION AND TREATMENT OF CANDER - The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by 01-05-2012
20120064059FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acids encoding the fusion proteins, methods of preparing same and uses thereof are also described.03-15-2012
20100291061PROCESS FOR MAKING OLIGOPEPTIDES - There is described a method of synthesising a family of oligopeptides of predetermined amino acid sequence, which together make up from 7 amino acids to the complete amino acid sequence of a target protein, which comprises: synthesising a nucleic acid construct which codes for a fusion protein composed of overlapping peptides derived from the desired portion of the target protein, interspersed with regions which code for protease cleavage sites, expressing the nucleic acid construct in a suitable expression vector, harvesting the fusion protein corresponding to the nucleic acid sequence, and digesting the fusion protein with a protease selective for the cleavage sites to generate the oligopeptides. The oligopeptides may be generated in vitro or in vitro and may be used as vaccines against viral infections and in epitope mapping.11-18-2010
20120058103COMPOSITION OF INDIVIDUAL PROTEOLYTIC ENZYMES - The invention relates to bioengineering, in particular to producing a composition of individual enzymes exhibiting the extended range of proteolytic activity, thereby enabling the composition to hydrolyse protein substrates up to individual amino acids. The composition contains at least two proteases, the molecular mass of which ranges from 23 to 36 kilodaltons and which have the following N-terminal amino acid sequences: I V G G T E V T P G E I P Y Q L S L Q D-I V G E V T P G E I P Y Q L S F Q D-I V G G Q E A S P G S W P X Q V G L F F-E A T S G Q F P Y Q X S F Q D-I V G G Q E A T P H T W V H Q V A L F E A T P H T X V H Q A L F I-A M D X T A Y X D Y D E I Q A X L K N T F E E I N S I L D G V-A A I L G D E Y L X S G G V V P Y V F G-Medicinal and cosmetic means containing the inventive composition of individual highly purified proteolytic enzymes in the form of an active agent make it possible to reduce the concentration of the composition during the use thereof due to the higher enzymatic activity and do not generate allergic reactions during a long term use. In addition, the composition formulation can be optimised (also standardised) with respect to a patient, thereby increasing the efficiency of the composition and reducing side effects of the use thereof.03-08-2012
20100291064Compounds and Methods for the Treatment of Vascular Disease - The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.11-18-2010
20100291062Antimicrobial Composition - A complex antimicrobial sorption composition possessing the necrolytic effect for treating the purulent wounds, the trophic ulcers, the wounds, and the infiltrates with the significant necrotic and exudative components represents the silica sorbent with the immobilized drug. Aerosil is used as a siliceous sorbent, and seratiopeptidase as a drug.11-18-2010
20100092451Combination Enzyme Therapy for Digestion of Dietary Gluten - A combination enzyme product consisting of a glutamine specific endoprotease and a prolyl endopeptidase is provided. Both enzymes are active and stable in the stomach and can therefore be administered as lyophilized powders or simple capsules/tablets. A ratio of the two enzymes is used to maximize their synergy.04-15-2010
20100092452Replenishment and Enrichment of Ocular Surface Lubrication - An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.04-15-2010
20100247509Fusion Proteins - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.09-30-2010
20120128652ENDOLYSIN PLYP40 - The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO:1. The present invention further relates to the nucleic acid molecules comprising a nucleotide sequence coding for the polypeptide, vectors comprising the nucleic acid molecules, and host cells for the expression of the polypeptides. In addition, the present invention relates to the use of the polypeptide as a human medical, veterinary medical or diagnostic substance, as an antimicrobial substance in food, in cosmetics, as disinfecting agent or in the environmental field.05-24-2012
20120213764NOVEL METHOD FOR THE PRODUCTION OF A ANTIMICROBIAL PEPTIDE - The present invention relates to a method of producing a peptide consisting of the amino acids 63 to 110 of dermcidin (SEQ ID NO: 3) comprising (a) culturing a host cell carrying a nucleic acid molecule encoding the peptide in an expressible form, and (b) optionally isolating the peptide from the culture. Furthermore, the invention relates to a nucleic acid molecule encoding a fusion protein comprising or consisting of (a) a peptide heterologous with regard to dermcidin protein-tag; and, C-terminally thereof (b) a peptide having the antimicrobial activity of dermcidin wherein the fusion protein contains an arginine residue located immediately N-terminally of the peptide of (b).08-23-2012
20120230976ROTHIA SPECIES GLUTAMINE ENDOPEPTIDASES AND USE THEREOF - Disclosed are glutamine endopeptidase enzymes from 09-13-2012
20120230975FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, which is located between the non-cytotoxic protease and the Targeting Moiety; and a translocation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; wherein the Targeting Moiety is BAM, β-endorphin, bradykinin, substance P, dynorphin and/or nociceptin. Nucleic acid sequences encoding the fusion proteins, methods of preparing same and uses thereof are also described.09-13-2012
20120213763MUTANTS OF STREPTOKINASE AND THEIR COVALENTLY MODIFIED FORMS - The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their covalently modified variants that are characterized by improved therapeutic properties, such as increased proteolytic stability, extended plasma half-lives, reduced immuno-reactivity and enhanced fibrin clot specificity. The method involves either incorporating additional cysteine residues, or substituting cysteine residues for naturally occurring amino acids into non-essential regions of the protein such that the catalytic activity of the resultant protein remains largely unaltered. These cysteine variants were further modified by covalently attaching a cysteine reactive polymer such as polyethylene glycol (PEG) or sulfhydryl-reactive moieties from a group that includes fluorophore, spin labels or other small conjugates. Disclosed herein are site-specific biologically active conjugates of Streptokinases and its covalently modified variants.08-23-2012
20120251519Endopeptidase Treatment of Smooth Muscle Disorders - The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a smooth muscle disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a smooth muscle disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a smooth muscle disorder, use of such TEMs in treating a smooth muscle disorder, and use of such TEMs and Clostridial toxins in treating a smooth muscle disorder.10-04-2012
20120251520ACE2 ACTIVATION FOR TREATMENT OF HEART, LUNG AND KIDNEY DISEASE AND HYPERTENSION - ACE2 activating compounds for prevention and treatment of cardiovascular disease, kidney disease, lung disease and hypertension are disclosed. Also disclosed are methods of diagnosing cardiovascular disease, kidney disease, lung disease and hypertension by measuring ACE2 expression or nucleotide polymorphism analysis.10-04-2012
20120171192METHODS AND MATERIALS FOR MODULATING DEUBIQUITINASES AND UBIQUITINATED POLYPEPTIDES - This document relates to methods and materials involved in modulating deubiquitinases (e.g., USP10 polypeptides) and/or ubiquitinated polypeptides (e.g., tumor suppressor polypeptides or mutant versions of tumor suppressor polypeptides). For example, methods and materials for increasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for decreasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for stabilizing tumor suppressor polypeptides (e.g., wild-type p53 polypeptides), methods and materials for de-stabilizing mutant versions of tumor suppressor polypeptides (e.g., mutant p53 polypeptides), and methods and materials for reducing cancer cell proliferation, increasing cancer cell apoptosis, and/or treating cancer (e.g., cancers having reduced levels of wild-type p53 polypeptides or cancers having increased levels of mutant p53 polypeptides) are provided. This document also provides methods and materials for identifying agonists or antagonists of USP10 polypeptide mediated stabilization of p53 polypeptides.07-05-2012
20120076768DIGESTIVE/LAXATIVE COMPOSITIONS - Described are digestive/laxative compositions and methods of manufacture and use of same. In a preferred embodiment, the invention provides for a digestive/laxative composition including actinidin. The actinidin is preferably contributed by inclusion of fruit of genus 03-29-2012
20090117092COLLAGENOLYTIC ACTIVE ENZYME CONTAINING COMPOSITIONS, AND THEIR USE IN THE DENTAL FIELD - The invention relates to a composition comprising at least one collagenolytic active enzyme with enzymatic activity at acidic pH for drilless enzymatic caries removal. Furthermore, the present invention relates to a process of producing this collagenolytic active enzyme comprising composition and to processes of removing caries. The invention also relates to the use of collagenolytic active enzyme comprising compositions for producing a treatment agent for dental applications.05-07-2009
20100303798Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such TVEMPs and compositions.12-02-2010
20080299108Peptides for Diagnostic and Therapeutic Methods for Celiac Sprue - Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. Analogs of such oligopeptides are useful in the inhibition of immune responses.12-04-2008
20120321611Replenishment and Enrichment of Ocular Surface Lubrication - An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.12-20-2012
20110223149PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active peptidomimetic macrocycles with improved properties, such as protease resistance, relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.09-15-2011
20110236367RAT CATHESPIN DIPEPTIDYL PEPTIDASE I (DPPI): CRYSTAL STRUCTURE AND ITS USES - The present invention relates to structural studies of dipeptidyl peptidase I (DPPI) proteins, modified dipeptidyl peptidase I (DPPI) proteins and DPPI co-complexes. Included in the present invention is a crystal of a dipeptidyl peptidase I (DPPI) and corresponding structural information obtained by X-ray crystallography from rat and human DPPI. In addition, this invention relates to methods for using structure co-ordinates of DDPI, mutants hereof and co-complexes, to design compounds that bind to the active site or accessory binding sites of DPPI and to design improved inhibitors of DPPI or homologues of the enzyme.09-29-2011
20100203033Kits, formulations and solutions having enzymatically- permissive amounts of visualization agents and uses thereof - The invention relates to a proteolytic enzyme which is capable of forming fibrin when it reacts with fibrinogen, a fibrin-glue kit and a fibrin-glue formulation comprising an enzymatically-permissive concentration of a visualization agent and to their use in methods for prevention and/or reduction of adhesions and/or methods for promotion of blood coagulation sealing or filling body surfaces.08-12-2010
20130017186ADHERENT ANTIMICROBIAL BARRIER AND SANITIZING AGENT - Provided are viscous and adherent food-safe antimicrobial compositions, and methods for using same in the immediate and residual decontamination of microbial-contaminated substrate surfaces, in reducing or precluding cutting implement-mediated transfer of surface contamination during cutting operations in the food industry, and for reducing or preventing transfer of contamination from contaminated surfaces in the food and pharmaceutical industries. Adherent antimicrobial protective layers are formed on substrate surfaces (e.g., processing equipment and utensils), providing a barrier (e.g., chemical and/or physical) to the passage or transport of microbial contamination between and among surfaces. The adherent formulations confer residual decontaminating activity, providing for prolonged killing of associated microbial contamination, are preferably formulated and applied as a gel, syrup or foam, and preferably comprise materials that are ‘generally-regarded-as-safe’ (GRAS) in food products, obviating post-treatment removal prior to consumption. Preferably, the inventive formulations are heated to a temperature ≧about 80° C. prior to application.01-17-2013
20110158976Enzymes for pharmaceutical use - The pharmaceutical use of proteases related to a protease derived from 06-30-2011
20110274682METHODS FOR PROTEASE ASSISTED PROTEIN DELIVERY - A method for intracellular delivery of single proteins or other cargo molecules by encapsulation within nanocapsules formed by interfacial polymerization of one or more types of monomers and selected protease cleavable cross-linkers is provided. The thin positively charged capsules are readily brought into the cytosol of target cells by endocytosis. The capsules are degraded by the action of endogenous proteases or co-delivered proteases on the cross-linkers releasing the functional cargo unaltered. The cross-linkers can be adapted to be cleavable by specific enzymes selected from available intracellular enzymes within the target cell or co-delivered or self-cleaving when the cargo itself is a protease. The nanocapsules produced by the methods have been shown to have long-term stability, high cell penetration capability, low toxicity and efficient protease-modulated specific degradability without affecting cargo protein function.11-10-2011
20120251518Endopeptidase Treatment of Sexual Dysfunction Disorders - The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a sexual dysfunction disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a sexual dysfunction disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a sexual dysfunction disorder, use of such TEMs in treating a sexual dysfunction disorder, and use of such TEMs and Clostridial toxins in treating a sexual dysfunction disorder.10-04-2012
20080213243Hemostatic materials and dressing - An adhesive material comprising gelatin and a non-toxic cross-linking material such as transglutaminase. The adhesive material is useful for medical purposes as hemostatic products. The hemostatic products are useful for the treatment of wounded tissue.09-04-2008
20100316624TREATMENT OF FIBROSES AND LIVER DISORDERS - The present invention relates to ACE2 for the therapeutic treatment or prevention of a fibrosis or liver disorder.12-16-2010
20110311509TREATMENT OF OCULAR DISEASES - The present invention relates to the use of at least one protease for the manufacture of a medicament for the treatment and/or prevention of ocular diseases related to neoangiogenesis selected from the group consisting of age related macular degeneration (AMD), choroidal neovascularisation, Hippel-Lindau Disease, iris neovascularisation, ischemic proliferative retinopathy, neovascularisation of the Cornea, and proliferative sickle cell retinopathy, wherein the at least one protease is selected from the group consisting of plant, non-mammalian animal and microbial proteases.12-22-2011
20120003205PHARMACEUTICAL COMPOSITION CONTAINING ARAZYME FOR THE PREVENTION OF LIVER DYSFUNCTION - The present invention relates to a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme as an active ingredient, more precisely a pharmaceutical composition for treating liver dysfunction which contains arazyme produced by 01-05-2012
20120020947COMPOSITIONS AND METHODS FOR INCREASING LEAN MUSCLE MASS AFTER EXERCISE - The present invention relates to novel methods and compositions comprising casein, creatine or derivatives of creatine, branched chain amino acids and proteases useful for increasing lean muscle mass after exercise.01-26-2012

Patent applications in class Acting on peptide bonds (3.4) (e.g., urokinease, etc.)

Patent applications in all subclasses Acting on peptide bonds (3.4) (e.g., urokinease, etc.)